

Applicants' undersigned representative encourages the Examiner to call if any additional information is required to allow these claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 10, 2003

By: 

Sean Myers-Payne
Reg. No. 42,920
ph. (571) 203-2717
fax (202) 408-4400
sean.myers-payne@finnegan.com

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



Appendix to Amendment

The claims are amended as follows:

1. (ONCE AMENDED) A method for preventing or treating gastrointestinal disease comprising administering an effective amount of [racemic pindolol or] S (-) pindolol₁ or a salt thereof₁ to a subject in need thereof.
4. (ONCE AMENDED) [A] The method according to claim 1₁ [in which] wherein an effective [amounts] amount of [RS-pindolol or] S(-) pindolol₁ or [their] its salts₁ [are] is administered in a pharmaceutical dosage form that permits rapid release of the [active substances] S(-) pindolol.
5. (ONCE AMENDED) [A] The method according to claim 1₁ [in which] wherein an effective [amounts] amount of [RS pindolol or] the S(-) pindolol₁ or [their] its salts₁ [are] is administered in a pharmaceutical dosage form that releases the [active substances] S(-) pindolol in a slow or controlled fashion.
6. (ONCE AMENDED) [A] The method according to claim 1₁ [in which] wherein the gastrointestinal diseases are [characterised as] selected from non-ulcerative dyspepsia₁ [or] irritable bowel syndrome₁ or chemotherapy-associated disorders of motility[, including nausea].
7. (NEW) The method according to claim 6, wherein the chemotherapy-associated disorders of motility include nausea.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com